Core Viewpoint - MicroPort NeuroTech (02172) reported a decline in revenue and profit for the first half of 2025, despite strong growth in international business [1] Financial Performance - Revenue for the period was approximately 383 million yuan, a year-on-year decrease of 6.2% [1] - Profit attributable to equity shareholders was 92.923 million yuan, down 35.25% year-on-year [1] - Earnings per share stood at 0.16 yuan [1] International Business Growth - The company's international business continued to show strong growth, with overseas revenue reaching 47.1 million yuan, an increase of 67.4% compared to the same period last year [1] - Profits from the international business segment experienced rapid growth [1] - Sales revenue in the Asia-Pacific, Europe, Middle East and Africa (EMEA), North America, and Latin America regions all saw varying degrees of rapid growth [1] Product Expansion - As of the end of the reporting period, the company had 8 products launched internationally, achieving commercialization in 34 overseas countries or regions [1] - The products cover 9 countries that rank among the top ten globally in terms of neuro-interventional procedures [1] - The company secured 9 product registrations in different overseas countries or regions, laying a solid foundation for scaling up overseas revenue [1]
微创脑科学(02172)公布中期业绩 权益股东应占溢利9292.3万元 同比减少35.25%